Luxembourg vs Peru: Access to anti-retroviral drugs, female
Luxembourg
87.0%
in 2024
Peru
86.0%
in 2024
Luxembourg rank
45th
Peru rank
47th
Access to anti-retroviral drugs, female over time
- Luxembourg
- Peru
How they compare
Luxembourg currently reports 87.0% against 86.0% in Peru, a difference of 1.0%.
The two have swapped places 4 times across 25 shared years of data; in 2000 it was Luxembourg ahead.
Luxembourg ranks 45th and Peru ranks 47th of 141 countries.
Luxembourg has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Luxembourg | Peru | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 43.3% | 12.3% | 31.0% | Luxembourg |
| 2010s | 64.1% | 59.6% | 4.5% | Luxembourg |
| 2020s | 80.2% | 78.0% | 2.2% | Luxembourg |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, female, Luxembourg or Peru?
- Luxembourg, at 87.0% against 86.0% in Peru as of 2024.
- What is the difference in access to anti-retroviral drugs, female between Luxembourg and Peru?
- 1.0%, with Luxembourg ahead.
- How many years of comparable data are there for Luxembourg and Peru?
- 25 years are reported by both, from 2000 to 2024.
- How do Luxembourg and Peru rank globally for access to anti-retroviral drugs, female?
- Luxembourg ranks 45th and Peru ranks 47th of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, female (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult females living with HIV who are receiving antiretroviral therapy.